BIO 2020: AI patents and secrets
Discussions around artificial intelligence (AI) and IP can sometimes be futuristic and trapped at the level of high-concept: whether machines can be inventors, for example. But at BIO Digital 2020, a panel of experts was on hand to provide a much more practical, down-to-earth guide to patenting AI inventions.
Roche and Innovent unite in $2bn biospecifics deal
Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.
Unitary SPC should follow new patent system: EC official
The European Commission wants to implement a unitary supplementary protection certificate, its top IP official has said.
US states sue 26 drugmakers over alleged price fixing
A coalition of attorneys general have taken 26 drugmakers, including Pfizer, Sandoz and Mylan, to court over the alleged price-fixing of topical generic drugs.
BIO 2020: Building your first patent portfolio
For a start-up looking to build a patent portfolio, where should you start—‘home-grown’ patents, or licensing others’ IP?
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.
Monster falls short in Merck TM dispute
Monster Energy has failed to block a UK trademark filed by German pharmaceutical company Merck KGaA.
No fees award for PTAB proceedings, rules Fed Circuit
The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Has the public got the taste for free medicine?
The COVID-19 pandemic has seen the fundamental principles of the IP system called into question. How can we go on as before?
AG advises CJEU to uphold €94 million pay-for-delay fine
The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.
